takeda pharmaceutical co
Editor’s Note – April 2015 Print Magazine
Check out our exclusive interviews with Takeda's Dr. Tachi Yamada and RIKEN's Professor Masayo Takahashi in the April 2015 print magazine!
Monash & Takeda Take On Gastrointestinal Disease
The research alliance between Monash and Takeda will investigate nano-medicine for gastrointestinal diseases, among other projects.
GE Healthcare & Takeda Form Alliance For Liver Disease
GE Healthcare's MR elastography technology will aid researchers in non-invasively assessing liver stiffness in the search for new drugs.
Takeda Invests In Vaccine Safe Co.
Alfresa's Vaccine Scheduling System helps parents keep track of their children's increasingly complex vaccination schedules.
Takeda Partners With American Therapeutic Accelerator BioMotiv
BioMotiv and Takeda pharmaceutical company enter into a strategic partnership to identify and develop pioneering medical innovations.
GHIT Awards Seven New Grants Amounting To US$15.3 Million
Research in the neglected tropical diseases of dengue, malaria and Chagas disease receive a US$15.3 million boost in funding from GHIT.
Sanofi & Takeda Partner For Diabetes
The partnership between Sanofi and Takeda aims to raise diabetes awareness and provide educational support for both patients and healthcare professionals.
MacroGenics & Takeda Develop Bi-Specific Antibodies For Autoimmune Diseases
MGD010, which simultaneously targets the cell surface receptors CD32B and CD78B, could help modulate B cell function without causing depletion.
Takeda Receives NDA Approval For Influenza Vaccine
Developed using cell culture-based technology, Takeda's H5N1 vaccine could help to strengthen Japan's pandemic preparedness.
